ViiV Goes After Lupin Over HIV Drug ANDA

Law360, New York (June 30, 2011, 7:33 PM EDT) -- ViiV Healthcare Co. filed a patent infringement suit against Lupin Ltd. in Delaware on Wednesday in an effort to block the Indian drugmaker’s planned generic version of HIV drug Trizivir.

U.K.-based ViiV claims that a Lupin abbreviated new drug application infringes the patent covering Trizivir, an anti-retroviral treatment that uses three different types of drugs to better treat resistant strains of HIV.

“ViiV will be irreparably harmed by Lupin’s infringing activities unless those activities are enjoined by this court,” the complaint said. “ViiV does not have...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.